JPH06507902A - 肝臓で代謝される薬物前駆物の決定とその治療的利用 - Google Patents
肝臓で代謝される薬物前駆物の決定とその治療的利用Info
- Publication number
- JPH06507902A JPH06507902A JP5500240A JP50024093A JPH06507902A JP H06507902 A JPH06507902 A JP H06507902A JP 5500240 A JP5500240 A JP 5500240A JP 50024093 A JP50024093 A JP 50024093A JP H06507902 A JPH06507902 A JP H06507902A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- tables
- formulas
- liver
- chemical formulas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (15)
- 1.動物体中の所望のサイトに、その構造中にケト基を有すると共に生物に影響 を与える化合物の有効量を送給することにより、動物体中に所望の生物学的効果 を与える方法において、該送給が、そのケト基が還元されていること以外前記化 合物に相当する構造を有し、肝臓アルデヒドオキシダーゼによって前記化合物に 酸化されることができる薬剤前駆化合物を動物に投与することからなり、それに より該薬剤前駆物が肝臓アルデヒドオキシダーゼによって酸化されて前記化合物 が肝臓中でその場で形成されることを特徴とする改良方法。
- 2.請求項1に記載の方法であって、該生物に影響を与える化合物が5−置換U dR化合物であり、薬剤前駆物がPdRである方法。
- 3.請求項2に記載の方法であって、該生物に影響を与える化合物が5−置換I UdR化合物であり、薬剤前駆物がIPdRである方法。
- 4.請求項1に記載の方法であって、該生物に影響を与える化合物が5−置換U dR化合物以外の化合物である方法。
- 5.請求項1に記載の方法であって、が5−置換UdR化合物以外の生物に影響 を与える化合物がヌクレレオシドまたはヌクレオシド塩基の同族体である方法。
- 6.請求項1に記載の方法であって、該生物に影響を与える化合物が5−置換ウ ラシルである方法。
- 7.請求項5に記載の方法であって、該生物に影響を与える化合物が、▲数式、 化学式、表等があります▼,▲数式、化学式、表等があります▼▲数式、化学式 、表等があります▼,▲数式、化学式、表等があります▼▲数式、化学式、表等 があります▼and▲数式、化学式、表等があります▼からなる群から選はれ、 式中.R、I、F、Br、Cl、−CH3、−OR1、−CF3、NO2、SR 1、−CH=CR2R3、−C≡CR3または,−N=N′′−N−であり、前 記R1は炭素原子数1ないし5、好ましくは1であるアルキル基であり、前記R 2とR3は各独立に水素、C1−C8のアルキルまたはハロゲンであり、R′は 水素、リボース、デオキシリボース、CH2−O−CH2−CH2OH、−CH 2−O−CH(CH2OH)、置換または未置換のアルキル基、アリール基、シ クロアルキル基、シクロアルキル基、シクロアリール基または肝臓アルデヒドロ キシダーゼの作用を立体的に傷害しない大きさの残基である前記方法。
- 8.請求項7に記載の方法であって、 該薬物前駆物のR′が ▲数式、化学式、表等があります▼,▲数式、化学式、表等があります▼,▲数 式、化学式、表等があります▼,▲数式、化学式、表等があります▼,▲数式、 化学式、表等があります▼,▲数式、化学式、表等があります▼,▲数式、化学 式、表等があります▼,▲数式、化学式、表等があります▼,▲数式、化学式、 表等があります▼▲数式、化学式、表等があります▼,▲数式、化学式、表等が あります▼,▲数式、化学式、表等があります▼,▲数式、化学式、表等があり ます▼▲数式、化学式、表等があります▼,▲数式、化学式、表等があります▼ ,▲数式、化学式、表等があります▼or▲数式、化学式、表等があります▼。 である方法。
- 9.請求項2に記載の方法であって、生物学的効果が肝臓中の治療である方法。
- 10.請求項1に記載の方法であって、該生物学的効果が肝臓に関連する疾病の 治療であり、該生物に影響を与える化合物が該肝臓に関連する疾病の治療に有効 である方法。
- 11.請求項10に記載の方法であって、動物がヒトである方法。
- 12.請求項1に記載の方法であって、該生物に影響を与える化合物が有効に経 口的に投与できないものであり、該薬物前駆物が経口的に投与できるものである 方法。
- 13.そのケト基が還元されていること以外、構造中にケト基を有する生物に影 響を与える化合物に相当する構造を有し、肝臓アルデヒドオキシダーゼによって 該化合物に酸化されることができる薬物前駆化合物の、該生物に影響を与える化 合物を投与することにより所望の生物学的効果を得るのに使用される薬物の製造 のための使用。
- 14.そのケト基が還元されていること以外、構造中にケト基を有する生物に影 響を与える化合物に相当する構造を有し、該生物に影響を与える化合物の投与に よって得られる所望の生物学的効果を得るために使用されるとき、肝臓アルデヒ ドオキシダーゼによって酸化されることができる薬剤前駆物。
- 15.実質的に無毒の薬物前駆物が疾病の治療に有効か否かを確認するための、 該薬剤前駆物を肝臓アルデヒドオキシダーゼと接触させ、生物に影響を与える化 合物に代謝されるか否かを決定する(その場合に薬物前駆物が生物に影響を与え る化合物に代謝されるならば、それは有効な該薬物前駆物である)ことからなる 方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70146291A | 1991-05-15 | 1991-05-15 | |
US701,462 | 1991-05-15 | ||
US82947492A | 1992-02-03 | 1992-02-03 | |
US829,474 | 1992-02-03 | ||
PCT/US1992/004142 WO1992020816A1 (en) | 1991-05-15 | 1992-05-15 | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06507902A true JPH06507902A (ja) | 1994-09-08 |
Family
ID=27106792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5500240A Abandoned JPH06507902A (ja) | 1991-05-15 | 1992-05-15 | 肝臓で代謝される薬物前駆物の決定とその治療的利用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5728684A (ja) |
EP (1) | EP0586523A4 (ja) |
JP (1) | JPH06507902A (ja) |
KR (1) | KR100245252B1 (ja) |
AU (1) | AU673803B2 (ja) |
BG (1) | BG98217A (ja) |
CA (1) | CA2103050A1 (ja) |
HU (1) | HUT67392A (ja) |
IE (1) | IE921581A1 (ja) |
IL (1) | IL101879A (ja) |
NO (2) | NO306850B1 (ja) |
RU (1) | RU2126255C1 (ja) |
WO (1) | WO1992020816A1 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9600847D0 (en) | 1996-01-16 | 1996-03-20 | Smithkline Beecham Plc | Pharmaceuticals |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
EP1109580A4 (en) | 1998-09-04 | 2004-05-26 | Viropharma Inc | METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES |
US6818227B1 (en) | 1999-02-08 | 2004-11-16 | Alza Corporation | Liposome composition and method for administration of a radiosensitizer |
JP2002539127A (ja) | 1999-03-08 | 2002-11-19 | メディキュア インコーポレーテッド | ビタミンb−6障害のためのピリドキサル類縁体 |
AU5922700A (en) * | 1999-07-09 | 2001-01-30 | Board Of Regents Of The University Of Nebraska, The | Therapy, prevention of recurrence, and diagnosis of colorectal cancer with radiopharmaceuticals |
US6489345B1 (en) | 1999-07-13 | 2002-12-03 | Medicure, Inc. | Treatment of diabetes and related pathologies |
EP1872797A3 (en) | 1999-08-24 | 2008-04-02 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US7442689B2 (en) * | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
WO2001064692A1 (en) | 2000-02-29 | 2001-09-07 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
JP2003528146A (ja) | 2000-03-28 | 2003-09-24 | メディキュア インターナショナル インコーポレイテッド | 脳血管疾患の治療 |
US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
CA2414188A1 (en) | 2000-07-07 | 2002-01-17 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
WO2003012051A2 (en) * | 2001-07-31 | 2003-02-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Inhibitor of dna methylation |
US7015022B2 (en) * | 2002-06-07 | 2006-03-21 | University Of Medicine & Dentistry Of New Jersey | Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities |
US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
JP2008505126A (ja) * | 2004-07-07 | 2008-02-21 | メディキュア インターナショナル インコーポレイテッド | 血小板凝集薬を用いる併用療法 |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US7459468B2 (en) * | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
CA2585165A1 (en) * | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
KR20080023680A (ko) | 2005-05-10 | 2008-03-14 | 인터뮨, 인크. | 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체 |
JP2009517411A (ja) * | 2005-11-28 | 2009-04-30 | メディキュア インターナショナル インコーポレーテッド | 心血管及び関連病状の処置のための調剤 |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
AU2010226466A1 (en) * | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
KR20130110170A (ko) | 2010-09-22 | 2013-10-08 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오타이드 유사체 |
US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
EP2827876A4 (en) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG |
RU2522548C2 (ru) * | 2012-09-26 | 2014-07-20 | Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) | Ингибитор уридинфосфорилаз |
RU2527457C2 (ru) * | 2012-09-27 | 2014-08-27 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2016057699A1 (en) | 2014-10-07 | 2016-04-14 | Kinsella Timothy J | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPdR) |
CA3049251A1 (en) | 2017-01-09 | 2018-07-12 | Shuttle Pharmaceuticals, Inc. | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation |
CN110494140A (zh) * | 2017-02-09 | 2019-11-22 | 完美日光有限公司 | 用于自闭症谱系障碍药物治疗的方法 |
EP4003508A1 (en) | 2019-07-31 | 2022-06-01 | Memorial Sloan Kettering Cancer Center | Perfusion modulated tumor dose sculpting with single dose radiotherapy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895937A (en) * | 1982-01-05 | 1990-01-23 | The Research Foundation Of State University Of New York | 5-ioso-2-pyrimidinone nucleoside |
US4468384A (en) * | 1982-01-05 | 1984-08-28 | The Research Foundation Of State University Of New York | Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides |
US4782142A (en) * | 1982-01-05 | 1988-11-01 | The Research Foundation Of State University Of New York | Novel 5-substituted 2-pyrimidinone nucleosides and methods of use |
EP0287215B1 (en) * | 1987-03-16 | 1992-06-17 | The Wellcome Foundation Limited | Therapeutic nucleosides |
US4942226A (en) * | 1988-12-29 | 1990-07-17 | Merck & Co., Inc. | Halogenated pyrimidine nucleosides and their derivatives |
WO1992001452A1 (en) * | 1990-07-19 | 1992-02-06 | The Wellcome Foundation Limited | Enzyme inactivators |
GB9020930D0 (en) * | 1990-09-26 | 1990-11-07 | Wellcome Found | Pharmaceutical combinations |
-
1992
- 1992-05-15 EP EP92912221A patent/EP0586523A4/en not_active Withdrawn
- 1992-05-15 RU RU93058654A patent/RU2126255C1/ru active
- 1992-05-15 US US08/146,164 patent/US5728684A/en not_active Expired - Fee Related
- 1992-05-15 WO PCT/US1992/004142 patent/WO1992020816A1/en active Application Filing
- 1992-05-15 IL IL101879A patent/IL101879A/en not_active IP Right Cessation
- 1992-05-15 HU HU9303237A patent/HUT67392A/hu unknown
- 1992-05-15 CA CA002103050A patent/CA2103050A1/en not_active Abandoned
- 1992-05-15 JP JP5500240A patent/JPH06507902A/ja not_active Abandoned
- 1992-05-15 AU AU19982/92A patent/AU673803B2/en not_active Ceased
- 1992-05-15 KR KR1019930703451A patent/KR100245252B1/ko not_active IP Right Cessation
- 1992-07-01 IE IE158192A patent/IE921581A1/en not_active Application Discontinuation
-
1993
- 1993-11-09 NO NO934059A patent/NO306850B1/no not_active IP Right Cessation
- 1993-11-12 BG BG98217A patent/BG98217A/bg unknown
-
1999
- 1999-05-11 NO NO992273A patent/NO308884B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BG98217A (bg) | 1995-02-28 |
RU2126255C1 (ru) | 1999-02-20 |
HU9303237D0 (en) | 1994-03-28 |
AU673803B2 (en) | 1996-11-28 |
EP0586523A4 (en) | 1995-11-29 |
US5728684A (en) | 1998-03-17 |
IE921581A1 (en) | 1992-11-18 |
KR100245252B1 (ko) | 2000-03-02 |
EP0586523A1 (en) | 1994-03-16 |
IL101879A (en) | 1998-06-15 |
NO934059D0 (no) | 1993-11-09 |
NO992273L (no) | 1999-05-11 |
NO308884B1 (no) | 2000-11-13 |
IL101879A0 (en) | 1992-12-30 |
CA2103050A1 (en) | 1992-11-16 |
HUT67392A (en) | 1995-04-28 |
NO992273D0 (no) | 1999-05-11 |
AU1998292A (en) | 1992-12-30 |
NO306850B1 (no) | 2000-01-03 |
NO934059L (no) | 1993-12-30 |
WO1992020816A1 (en) | 1992-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06507902A (ja) | 肝臓で代謝される薬物前駆物の決定とその治療的利用 | |
CN100528173C (zh) | 4′-取代的核苷 | |
KR101774429B1 (ko) | 암 및 바이러스 감염 치료용 퓨린 뉴클레오시드 모노포스페이트 프로드럭 | |
US6949522B2 (en) | β-2′- or 3′-halonucleosides | |
JP3001972B2 (ja) | 5―ベンジルバルビツレート誘導体 | |
US20040110718A1 (en) | Anti-HCV nucleoside derivatives | |
CA2223640A1 (en) | Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated pyrimidine nucleosides | |
JP3621102B2 (ja) | 新規な酵素阻害剤、その合成及び使用方法 | |
JPH06508846A (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療 | |
Shewach et al. | Potentiation of 2′-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine | |
JPH11512397A (ja) | 治療用アジド化合物 | |
US6870052B2 (en) | Preparation of thioarabinofuranosyl compounds and use thereof | |
US4650801A (en) | Anti-cancer compositions for delivering 5-fluorouracil | |
JPS6337766B2 (ja) | ||
Burns et al. | Novel 6-alkoxypurine 2', 3'-dideoxynucleosides as inhibitors of the cytopathic effect of the human immunodeficiency virus | |
US5041542A (en) | Substituted pyrimido[5,4-d]pyrimidine nucleosides | |
JP2688057B2 (ja) | 抗腺がん剤 | |
Modi et al. | The physiological and medicinal potential pyrimidines & different scheme to synthesize pyrimidine heterocycles: An update | |
US7217815B2 (en) | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents | |
JPH10507763A (ja) | L−ピラノシルヌクレオシド | |
Cha | Development of inhibitors of pyrimidine metabolism | |
US4720497A (en) | 6-purinyl N-/2-chloroethyl/carbamate and thiocarbamate and process for the preparation thereof | |
IL121375A (en) | Preparation of compositions of prodrugs metabolizable by the liver | |
JPH06172365A (ja) | 10−チアイソアロキサジン誘導体およびその用途 | |
CA2464681C (en) | Preparation of thioarabinofuranosyl compounds and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20031202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040326 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040326 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040708 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20041021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051012 |
|
A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20070419 |